Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi.
Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
Am J Physiol Renal Physiol. 2019 Dec 1;317(6):F1409-F1413. doi: 10.1152/ajprenal.00380.2019. Epub 2019 Sep 30.
Macrophages are heterogenous cells of the innate immune system that can fluidly modulate their phenotype to respond to their local microenvironment. They are found throughout the renal compartments, where they contribute to homeostasis and function. However, renal injury activates molecular pathways that initially stimulate differentiation of macrophages into a proinflammatory M1 phenotype. Later in the course of healing, abundant apoptotic debris and anti-inflammatory cytokines induce the production of anti-inflammatory M2 macrophages, which contribute to tissue regeneration and repair. Thus, the dynamic balance of M1 and M2 populations may outline the burden of inflammation and process of tissue repair that define renal outcomes, which has been the impetus for therapeutic efforts targeting macrophages. This review will discuss the role of these phenotypes in the progression of chronic renal injury, potential pathogenic mechanisms, and the promise of macrophage-based therapeutic applications for chronic kidney disease.
巨噬细胞是先天免疫系统的异质性细胞,可以灵活地调节其表型以响应其局部微环境。它们存在于肾脏的各个部位,在那里它们有助于维持体内平衡和发挥功能。然而,肾脏损伤会激活分子途径,最初刺激巨噬细胞分化为促炎 M1 表型。在愈合过程的后期,大量凋亡的碎片和抗炎细胞因子诱导抗炎 M2 巨噬细胞的产生,有助于组织再生和修复。因此,M1 和 M2 群体的动态平衡可能概述了炎症负担和组织修复过程,从而定义了肾脏结局,这一直是针对巨噬细胞的治疗努力的动力。这篇综述将讨论这些表型在慢性肾脏损伤进展中的作用、潜在的发病机制,以及基于巨噬细胞的治疗应用在慢性肾病中的前景。